Sarepta Therapeutics, Inc.
SRPT
Rank in Stocks
#6250
Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company... Sarepta Therapeutics, Inc. is a commercial-stage biopharmaceutical company dedicated to the discovery and advancement of genetic treatment modalities, including RNA-targeted therapeutics and gene therapies, specifically for rare diseases. The company currently offers two approved treatments: EXONDYS 51, prescribed for Duchenne muscular dystrophy (DMD) patients with confirmed dystrophin gene mutations amenable to exon 51 skipping, and VYONDYS 53, for DMD patients with exon 53 skipping mutations. Sarepta's development pipeline includes AMONDYS 45, an exon-skipping product candidate utilizing phosphorodiamidate morpholino oligomer chemistry for exon 45; SRP-5051, a peptide-conjugated PMO designed to target exon 51 of dystrophin pre-mRNA; and gene therapy programs such as SRP-9001 for DMD and SRP-9003 for limb-girdle muscular dystrophies. The company maintains collaborative agreements with organizations like F. Hoffman-La Roche Ltd, Nationwide Children's Hospital, Lysogene, Duke University, Genethon, and StrideBio. Founded in 1980, Sarepta Therapeutics is headquartered in Cambridge, Massachusetts.
Share Price
$17.24
Last synced: 2026-11-09
Market Cap
$1.82B
Change (1 day)
-3.25%
Change (1 year)
-4.12%
Country
Stock data: Financial Modeling PrepΒ·Updated Β·Not investment adviceΒ·How we calculate this
Trade Sarepta Therapeutics, Inc. (SRPT)
Category
Healthcare
EPS for Sarepta Therapeutics, Inc. (SRPT)
EPS as of September 2026 TTM: $0.09
According to Sarepta Therapeutics, Inc.'s latest financial reports, its current EPS (TTM) is $0.09. At the end of 2025 the company had an EPS of $-7.13, a decrease compared to its 2024 EPS of $2.47.
EPS history for Sarepta Therapeutics, Inc. from 2000 to 2026
EPS at the end of each year
| Year | EPS | Change |
|---|---|---|
| 2026 (TTM) | $0.09 | -101.26% |
| 2025 | $-7.13 | -388.66% |
| 2024 | $2.47 | -142.59% |
| 2023 | $-5.80 | -27.77% |
| 2022 | $-8.03 | 55.92% |
| 2021 | $-5.15 | -27.57% |
| 2020 | $-7.11 | -26.78% |
| 2019 | $-9.71 | 77.84% |
| 2018 | $-5.46 | 534.88% |
| 2017 | $-0.86 | -84.34% |
| 2016 | $-5.49 | 5.58% |
| 2015 | $-5.20 | 53.39% |
| 2014 | $-3.39 | 2.42% |
| 2013 | $-3.31 | -35.60% |
| 2012 | $-5.14 | 4,572.73% |
| 2011 | $-0.11 | -93.68% |
| 2010 | $-1.74 | 7.41% |
| 2009 | $-1.62 | -21.74% |
| 2008 | $-2.07 | -31.46% |
| 2007 | $-3.02 | -14.69% |
| 2006 | $-3.54 | 58.04% |
| 2005 | $-2.24 | -45.76% |
| 2004 | $-4.13 | 40.48% |
| 2003 | $-2.94 | -57.14% |
| 2002 | $-6.86 | -4.85% |
| 2001 | $-7.21 | 143.58% |
| 2000 | $-2.96 | 0.00% |
EPS for similar companies or competitors
| Company | EPS | EPS Difference | Country |
|---|---|---|---|
| $15.66 | 17,300.00% |
US
|
|
| $-7.07 | -7,955.56% |
US
|
|
| $-5.29 | -5,977.78% |
AU
|
|
| $12.88 | 14,211.22% |
BE
|
|
| $21.56 | 23,855.56% |
NL
|
Questions about Sarepta Therapeutics, Inc.'s earnings per share (EPS)
What is Sarepta Therapeutics, Inc.'s earnings per share (EPS)?
Sarepta Therapeutics, Inc.'s earnings per share (EPS) over the last twelve months is $0.09, as of Sep 2026.
What was Sarepta Therapeutics, Inc.'s earnings per share (EPS) in 2025?
In 2025, Sarepta Therapeutics, Inc.'s earnings per share (EPS) was $-7.13, compared with $2.47 in 2024.
How has Sarepta Therapeutics, Inc.'s earnings per share (EPS) changed since 2020?
From 2020 to 2025, Sarepta Therapeutics, Inc.'s earnings per share (EPS) was highest in 2024 ($2.47) and lowest in 2022 ($-8.03).
How does Sarepta Therapeutics, Inc.'s earnings per share (EPS) compare with similar companies?
Sarepta Therapeutics, Inc.'s earnings per share (EPS) ($0.09) is higher than that of 2 of the 5 similar companies listed above. The highest among them is Argenx SE, with $21.56.